Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)

Norio Komatsu, Keita Kirito, Kazuya Shimoda, Takayuki Ishikawa, Kohshi Ohishi, Kazuma Ohyashiki, Naoto Takahashi, Hikaru Okada, Taro Amagasaki, Toshio Yonezu, Koichi Akashi

Research output: Contribution to journalComment/debate

Abstract

The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading: The first sentence in the “Results” section under the heading“Patients” should read as“A total of 51 patients were enrolled in this study from April 2014 to September 2014.”

Original languageEnglish
Pages (from-to)387
Number of pages1
JournalInternational journal of hematology
Volume105
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (International Journal of Hematology, (2017), 105, 3, (309-317), 10.1007/s12185-016-2130-z)'. Together they form a unique fingerprint.

  • Cite this